Compare
Bio-Techne Corp vs Qiagen N.V. vs Monte Rosa Therapeutics, Inc. vs Gilead Sciences, Inc.
| Latest fiscal year | Bio-Techne Corp TECH | Qiagen N.V. QGEN | Monte Rosa Therapeutics, Inc. GLUE | Gilead Sciences, Inc. GILD |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.22B | $2.09B | $123.67M | $29.44B |
| Revenue growth (YoY) | -0.4% | +5.7% | +63.5% | +2.4% |
| Gross margin | 65.8% | 62.2% | n/a | 78.8% (computed) |
| Operating margin | 20.7% | 22.3% | -43.8% | 34.0% |
| Net margin | 15.0% | 20.3% | -31.2% | 28.9% |
| Net income | $181.86M | $424.88M | -$38.63M | $8.51B |
| EPS (Diluted) | $1.16 | $1.94 | n/a | $6.78 |
| Operating cash flow | $292.07M | $654.33M | -$22.80M | $10.02B |
| Free cash flow | $263.22M | $453.28M | -$27.50M | $9.46B |
| Cash & equivalents | $264.71M | $839.00M | $129.88M | n/a |
| Total assets | $2.59B | $6.28B | $448.66M | $59.02B |
| Total liabilities | n/a | n/a | $215.60M | n/a |
| Shareholders' equity | $2.11B | $3.78B | $233.06M | $22.62B |
| Return on year-end equity | 8.6% | 11.2% | -16.6% | 37.6% |
| Shares outstanding | 156.10M | n/a | 65.54M | 1.24B |
Revenue, most recent five fiscal years
| Fiscal year | Bio-Techne Corp | Qiagen N.V. | Monte Rosa Therapeutics, Inc. | Gilead Sciences, Inc. |
|---|---|---|---|---|
| Latest | $1.22B Ended 2026-06-30 | $2.09B Ended 2025-12-31 | $123.67M Ended 2025-12-31 | $29.44B Ended 2025-12-31 |
| 1 year earlier | $1.22B Ended 2025-06-30 | $1.98B Ended 2024-12-31 | $75.62M Ended 2024-12-31 | $28.75B Ended 2024-12-31 |
| 2 years earlier | $1.16B Ended 2024-06-30 | $1.97B Ended 2023-12-31 | $0 Ended 2023-12-31 | $27.12B Ended 2023-12-31 |
| 3 years earlier | $1.14B Ended 2023-06-30 | $2.14B Ended 2022-12-31 | n/a | $27.28B Ended 2022-12-31 |
| 4 years earlier | $1.11B Ended 2022-06-30 | $2.25B Ended 2021-12-31 | n/a | $27.30B Ended 2021-12-31 |